Evidence map›Paper›PMID 41404347›Full record

ArticleFrontiers in ophthalmology2025

Therapeutic potential of taurine in a pigmented rat model of age-related macular degeneration.

Mohammed Attia, Tonja Pavlovic, Ashley Muliawan, Farjana Tuya, Maria Mihalatos, Marcin Iwanicki, Jennifer Kang-Mieler

Abstract read
In one paragraph

Article in Frontiers in ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Mohammed AttiaDepartment of Biomedical Engineering, Stevens Institute of Technology, Hoboken, NJ, United States.
Tonja PavlovicDepartment of Chemistry and Chemical Biology, Stevens Institute of Technology, Hoboken, NJ, United States.
Ashley MuliawanDepartment of Biomedical Engineering, Stevens Institute of Technology, Hoboken, NJ, United States.
Farjana TuyaDepartment of Biomedical Engineering, Stevens Institute of Technology, Hoboken, NJ, United States.
Maria MihalatosDepartment of Chemistry and Chemical Biology, Stevens Institute of Technology, Hoboken, NJ, United States.
Marcin IwanickiDepartment of Chemistry and Chemical Biology, Stevens Institute of Technology, Hoboken, NJ, United States.
Jennifer Kang-MielerDepartment of Biomedical Engineering, Stevens Institute of Technology, Hoboken, NJ, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: To investigate the potential protective effects of taurine supplementation against retinal degeneration in an animal model of mild dry age-related macular degeneration (AMD). Methods: To test the effects of a taurine supplement in mild dry AMD, sodium iodate (NaIO Results: The high-dose IV model (80 mg/kg) exhibited extensive and severe retinal damage, with ONL thinning by 64.2% and total retinal thickness (TRT) by 47.6%, predominantly in the peripapillary region. In contrast, the lower-dose IP model (50 mg/kg) displayed milder, more gradual deterioration (outer nuclear layer (ONL) thinning by 19.4% and TRT by 11.5%). Oral taurine supplementation significantly preserved ONL and TRT Conclusion: Taurine supplementation provided significant structural protection against NaIO

Indexed as

dry age-related macular degeneration (AMD)oxidative stressretinal pigment epithelium (RPE)retinal thicknesssodium iodatetaurine

Identifiers

PMID41404347
PMCPMC12702761

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.